Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
- Conditions
- Alport Syndrome
- Interventions
- Drug: Vonafexor
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT06425055
- Locations
- 🇺🇸
Dr Eric Wallace - University of Alabama, Birmingham, Alabama, United States
🇺🇸Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Dr Arnold Silva - Boise Kidney & Hypertension, Boise, Idaho, United States
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 26
- Registration Number
- NCT04465916
- Locations
- 🇵🇱
ENYO PHARMA Investigative site PL01, Białystok, Poland
🇵🇱ENYO PHARMA Investigative site PL02, Lublin, Poland
🇵🇱ENYO PHARMA Investigative site PL03, Warszawa, Poland
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT04365933
- Locations
- 🇰🇷
ENYO PHARMA Investigative site KR01, Busan, Korea, Republic of
🇨🇳ENYO PHARMA Investigative site TW03, Kaohsiung, Taiwan
🇨🇳ENYO PHARMA Investigative site TW04, Kaohsiung, Taiwan
Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose
- Conditions
- Healthy
- Interventions
- Drug: [14C]-EYP001a
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 6
- Registration Number
- NCT04037618
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
- Conditions
- NASH - Nonalcoholic SteatohepatitisHealthy
- Interventions
- Drug: EYP001a
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT03976687
- Locations
- 🇦🇺
ENYO Pharma clinical site, Randwick, New South Wales, Australia
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: VonafexorOther: Placebo
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT03812029
- Locations
- 🇺🇸
ENYO PHARMA Investigative site 0413, Baton Rouge, Louisiana, United States
🇺🇸ENYO PHARMA Investigative site 0422, Baltimore, Maryland, United States
🇧🇪ENYO PHARMA Investigative site 0103, Gent, Belgium
Drug Drug Interaction Study for EYP001 With Entecavir
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT03469583
- Locations
- 🇦🇺
Cmax Clinical Research Pty Ltd, Adelaide, South Australia, Australia
EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: EYP001a
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 11
- Registration Number
- NCT03320616
- Locations
- 🇳🇱
PRA-EDS, Groningen, Netherlands
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 73
- Registration Number
- NCT03272009
- Locations
- 🇦🇺
Scientia Clinical Research Limited, Sydney, New South Wales, Australia
🇳🇱Academic Medical Centre (AMC), Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: EYP001aDrug: Placebo
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 80
- Registration Number
- NCT03110276